Medicare GLP-1 Bridge Program:
What Medicare Beneficiaries Need to Know
Beginning July 1, 2026, the Centers for Medicare & Medicaid Services (CMS) will launch the Medicare GLP-1 Bridge Program, a temporary demonstration program that may help eligible Medicare beneficiaries access certain FDA-approved weight loss medications at a reduced cost.
The program is scheduled to run through December 31, 2027, and operates separately from standard Medicare Part D prescription drug coverage.
What Is the Medicare GLP-1 Bridge Program?
The Medicare GLP-1 Bridge Program is a temporary CMS demonstration designed to provide access to certain FDA-approved GLP-1 medications for weight management. The program was created to help eligible Medicare beneficiaries obtain medications that are generally not covered under traditional Medicare Part D rules for weight loss.
Unlike standard Medicare prescription drug coverage, this program is administered directly by CMS through a centralized system.
When Does the Program Begin?
The Medicare GLP-1 Bridge Program will:
Begin July 1, 2026
Continue through December 31, 2027
Because this is a demonstration program, it is temporary and may be modified or discontinued by CMS at any time.
Who May Be Eligible?
According to CMS guidelines, beneficiaries must be enrolled in Medicare Part D and meet specific clinical criteria established by Medicare.
Potential eligibility may include individuals who are:
Age 18 or older with a Body Mass Index (BMI) of 35 or higher
Age 18 or older with a BMI of 30 or higher and certain qualifying health conditions, such as:
Heart failure
Uncontrolled hypertension
Chronic kidney disease
Individuals with a BMI of 27 or higher who have certain qualifying conditions, including:
Pre-diabetes
A previous heart attack
A previous stroke
Meeting these criteria does not guarantee approval. Medicare will determine eligibility based on clinical requirements and supporting documentation submitted by the beneficiary's healthcare provider.
Which Medications Are Included?
At the launch of the program, CMS has identified the following medications as eligible under the Bridge Program:
Wegovy®
Zepbound®
Foundayo®
CMS may modify the list of covered medications during the course of the demonstration program.
How Much Will It Cost?
For beneficiaries who are approved through the program, the expected cost is:
$50 per 30-day supply
The cost-sharing amount is established by CMS and is separate from Medicare Part D cost-sharing requirements.
How Does the Application Process Work?
Beneficiaries cannot enroll themselves directly in the program.
If you believe a GLP-1 medication may be appropriate for you, the first step is to speak with your healthcare provider.
Your healthcare provider will:
Determine whether a GLP-1 medication is medically appropriate
Review Medicare Eligibility Requirements
Complete and submit the required CMS Prior Authorization documentation
Provide supporting medical information when necessary
CMS uses a centralized processor to review prior authorization requests, process claims, and reimburse pharmacies.
Important Things to Understand
Before considering the Medicare GLP-1 Bridge Program, beneficiaries should understand:
The program operates separately from Medicare Part D plans.
Medicare Part D coverage rules for weight loss medications have not changed.
Medicare, not your Medicare plan, determines eligibility and approval.
Prior authorization is required.
Not all beneficiaries will qualify.
The program is temporary and currently scheduled to end on December 31, 2027.
Costs paid through the Bridge Program do not count toward Medicare Part D deductibles, out-of-pocket limits, or other Part D accumulations.
Why This Matters
Prescription drug costs can be a significant healthcare expense during retirement. For some Medicare beneficiaries who meet the program's clinical requirements, the Medicare GLP-1 Bridge Program may provide access to certain weight management medications at a predictable monthly cost.
If you are interested in learning whether you may qualify, speak with your healthcare provider. They can evaluate your medical situation and determine whether participation in the program may be appropriate.
How Otium Financial Planners Can Help
Healthcare expenses are an important part of retirement planning. At Otium Financial Planners, we help individuals understand how healthcare costs, Medicare expenses, and prescription drug spending fit into their overall retirement strategy.
While Otium Financial Planners does not determine eligibility, approve coverage, or administer the Medicare GLP-1 Bridge Program, our team can help you evaluate how healthcare expenses may affect your retirement income and long-term financial goals.
Final Thoughts
The Medicare GLP-1 Bridge Program is a temporary CMS demonstration that may provide eligible Medicare beneficiaries with access to certain FDA-approved weight loss medications for a flat monthly copayment.
Because eligibility is based on specific clinical criteria and requires healthcare provider involvement, beneficiaries interested in the program should begin by discussing their options with their physician or other qualified healthcare professional.
For the most current information, visit Medicare's official GLP-1 Bridge Program resources or speak with your healthcare provider.
Medicare Disclaimer
This information is provided for educational purposes only and is not affiliated with or endorsed by Medicare, CMS, or the federal government. We do not offer every plan available in your area. Currently, we represent multiple organizations which offer multiple products. Please contact Medicare.gov, 1-800-MEDICARE, or your local State Health Insurance Assistance Program (SHIP) for information on all available options.
Information is subject to change. Eligibility, coverage, approvals, participating medications, and program requirements for the Medicare GLP-1 Bridge Program are determined solely by CMS and may change without notice. This information is not medical advice. Beneficiaries should consult their healthcare provider regarding treatment options and program eligibility.